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Abstract
Osteopontin (OPN) is a pleiotropic protein, important in bone remodeling and immune 
system signaling. OPN is synthesized in a variety of cells and tissues. It can be found 
not only in bone cells but also in immune cells (B and T lymphocytes, natural killer (NK) 
cells, natural killer T (NKT) cells, macrophages, neutrophils, and dendritic cells). OPN 
regulates T-helper 1/T-helper 2 (Th1/Th2) balance, stimulates B cells to antibodies pro-
duction, regulates macrophages and neutrophils function, and activates dendritic cells. 
A number of factors, including hormones, cytokines, and polymorphisms of promoter 
region of OPN gene, regulate protein expression. OPN and variants of the OPN gene 
have been associated with the pathogenesis of multiple disorders, including systemic 
lupus erythematosus, multiple sclerosis, rheumatoid arthritis, systemic sclerosis, inflam-
matory bowel diseases, asthma, type 1 diabetes, and many other. However, some studies 
gave different or inconclusive results. Thus, the role of OPN polymorphic variants in 
autoimmune diseases needs to be better defined and explored as a diagnostic and thera-
peutic target to monitor and treat immune-mediated conditions.
Keywords: asthma, autoimmune, gene, immunomodulation, inflammatory bowel diseases, 
multiple sclerosis, osteopontin, polymorphism, rheumatoid arthritis, sarcoidosis, systemic 
lupus erythematosus, systemic sclerosis, type 1 diabetes
1. Introduction
There are more than 200 genetic loci that have been associated with one or more disorders. 
Today, at least 90 autoimmune diseases have been identified [1]. The etiology of autoimmune 
diseases is not fully elucidated; however, the causes are likely based on a combination of 
environmental and genetic factors, which lead to immunological abnormalities [2, 3]. Recent 
genome-wide association studies (GWAS) and single-nucleotide polymorphism (SNP) arrays 
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have allowed the identification of several genetic variants associated with immune-mediated 
disorders. Genetic polymorphisms can influence the susceptibility, clinical manifestations, 
as well as response to therapy [4, 5].
A wide spectrum of inflammatory and immune mediators is currently under investigation 
in the context of autoimmune diseases. One of them is osteopontin (OPN), also known 
as early T lymphocyte activation-1 (Eta-1) or secreted phosphoprotein 1 (SPP-1). OPN is 
a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family 
proteins [6, 7]. OPN was identified in 1986 as a major sialoprotein of bone [8], where is 
involved in many biological processes, such as biomineralization and remodeling [9]. OPN 
is synthesized in a variety of cells and tissues. It can be found in bone cells, immune cells 
(B and T lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, macrophages, 
neutrophils, dendritic cells), breast epithelial cells, neurons, Kupffer cells, hepatic macro-
phages, hepatic stellate cells (HSCs), lung cells, adipocytes, and many other [10]. OPN is a 
pleiotropic protein and its functions are linked to various physiological processes and path-
ological conditions. OPN, secreted by osteoblasts, osteoclasts, and osteocytes, is important 
in mineralization and bone resorption [9]. Recently, this protein was found to be relevant in 
regulation of immunity and inflammation, angiogenesis, oncogenesis, cancer progression, 
and apoptosis [10–12]. OPN interacts with most cells using two binding domains. Signaling 
via integrins (αvβ1, αvβ3, αvβ5, αvβ6, α8β1, α5β1, α9β1, α4β1, and α4β7) modulates the 
phosphorylation of kinases, which are involved in nuclear factor-kappa B (NF-κB) activa-
tion and regulation of cytokines production [13–16]. Moreover, OPN is an extracellular 
ligand for CD44 receptors. Signaling through CD44 modulates T cell chemotaxis, fibroblast 
adhesion, and interleukin (IL)-10 gene expression in macrophages [17]. OPN expression 
and function are influenced by post-translational modifications (phosphorylation, O-linked 
glycosylation, sialylation, tyrosine sulfation), hormones (calcitriol, retinoid acid, steroids), 
pro-inflammatory cytokines, growth and differentiation factors (epidermal growth factor, 
platelet-derived growth factor, transforming growth factor beta), and genetic polymor-
phisms of its promoter [18].
2. Osteopontin gene—structure and polymorphism
The human OPN gene (OPN) is mapped on the long arm of chromosome 4 (4q21-4q25). OPN 
contains seven exons (protein-coding regions) and six introns. The gene spans ∼9 kb. The 
open reading frame (ORF) consists of 942 nucleotides from the start codon (in exon 2) to the 
stop codon (in exon 7) [19]. The 5′-untranslated (5′-UTR) region, of 67 bases, contains exon 1, 
which starts with transcription start site AGC (also referred to as the GCC box). The 3′-UTR 
region, of 415 bases, consists of the last part of exon 7 and includes three polyadenylation 
signals (AATAA). Exons 2–7 contain coding sequences: signal peptide and two first amino 
acids (exon 2), two Ser-Ser-Glu-Glu phosphorylation sequences (exons 3 and 5), two trans-
glutaminase-reactive glutamine residues (exon 4), and aspartic acid-rich sequence (exon 6). 
Exon 7 encodes about half of the protein and contains the RGD motif and the central thrombin 
cleavage site [20].
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OPN is highly polymorphic. Several polymorphisms in the human OPN gene have been 
identified. Single-nucleotide polymorphisms (SNPs) have been proposed as a tool for iden-
tifying genes associated with multiple autoimmune disorders. Polymorphisms in a human 
OPN have been reported to exhibit functional implications and have been evaluated in several 
conditions. Genetic association studies have suggested that some OPN SNPs may serve as a 
potential marker to predict immune-mediated diseases in some populations.
3. Osteopontin gene polymorphism and autoimmune diseases
3.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease. SLE is 
caused by environmental, hormonal, and genetic factors, which lead to immunological dysfunc-
tion [21, 22]. Deregulation of B and T lymphocytes activation leads to abnormalities in cytokine 
expression and production of autoantibodies, which form complexes with antigens. Complexes 
are deposited in organs and cause inflammation and tissue damage [23, 24]. Deregulation in 
cytokine expression is also a cause of tissue injury [25]. OPN promotes activation of T lympho-
cytes and regulates the T-helper 1/T-helper 2 (Th1/Th2) balance. OPN upregulates IL-12 pro-
duction and downregulates IL-10 [26]. Recent findings revealed that OPN enhances interferon 
(IFN)-α expression through the interferon regulatory factor 7 (IRF7) activation upon toll-like 
receptor (TLR)9 stimulation in plasmacytoid dendritic cells (pDCs) [27] and stimulates anti-
bodies production by B lymphocytes [26, 28]. In addition, it has been demonstrated that OPN 
enhances IL-17 producing Th17 cell responses [29, 30]. Thus, OPN plays an important role 
in regulating inflammation and immunity. Therefore, several studies have been performed to 
assess the association of OPN and predisposition to SLE.
In the literature, there are reports suggesting that OPN participates in the pathogenesis of SLE. 
It has been demonstrated that serum OPN level is elevated in SLE patients [31–36]. Moreover, 
OPN level correlates positively with disease activity index [33–35]. Polymorphic OPN alleles 
have been implicated in the mouse model of lupus [37]. The association between OPN gene 
polymorphisms and SLE susceptibility in humans has also been investigated.
In 2002, a study of Forton et al. [38] showed that polymorphic T allele of the polymorphism 
at position 707 in exon 7 (707C/T, rs1126616) is associated with opportunistic infections and 
renal insufficiency but is protective for avascular necrosis in Caucasian SLE patients. This was 
the first demonstration of a phenotypic association with an OPN polymorphism.
In a study of D’Alfonso et al. [39], a total of 13 SNPs in OPN gene were identified (six in the 
5’ flanking region, one in intron 3, three in exons 6, 7 and three in the 3’-UTR). Two polymor-
phisms: −156G/GG (rs7687316, in promoter) and +1239A/C (rs9138, in 3′-UTR) were signifi-
cantly associated with SLE. The −156G and +1239C alleles were more frequent in SLE patients 
than in the control group. In addition, significant association was seen between lymphade-
nopathy and −156 genotypes. Significantly increased OPN serum level was detected in healthy 
individuals carrying +1239C.
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In 2007, Xu et al. [40] demonstrated that SNP at position 9250 in exon 7 of the OPN gene 
(9250C/T) exists in the Chinese Han ethnic population and is associated with SLE. The fre-
quency of TT genotype was lower and the frequency of TC genotype was higher in SLE 
patients than in controls. When authors separated patients and controls into women and men, 
significant differences of frequencies were noted in TT genotype, TC genotype and allele in 
women, but not in men. Moreover, the TT genotype was lower in SLE patients with lupus 
nephritis (LN) [41].
In a large study of SLE patients, Han et al. [42] reported that minor alleles of rs1126616 and 
rs9138 (T and C, respectively) were correlated with higher risk of SLE in European-American 
and African-American populations (in males, not in females). In addition, haplotype analysis 
identified rs1126616T-rs1126772A-rs9138C which demonstrated association with SLE in gen-
eral, especially in males. It was the first description of a gender-specific human lupus genetic 
association.
In another study, Trivedi et al. [43] genotyped the rs11730582, rs28357094, rs6532040, and 
rs9138 SNPs in the OPN gene in SLE patients. The group proved that photosensitivity was 
associated with the risk allele rs9138C. In addition, the study demonstrated that the C allele of 
rs11730582 polymorphism is associated with thrombocytopenia and hemolytic anemia.
Kariuki et al. [44] revealed an association of the rs9138C allele with higher levels of OPN and 
INF-α in male SLE patients. Moreover, two SNPs, rs11730582 and rs28357094, were associated 
with the presence of anti-ribonucleoprotein (anti-RNP) autoantibodies.
Salimi and colleagues [36] genotyped the rs1126616 SNP in SLE patients and age, gender, and 
ethnically matched controls. There was no association between the polymorphism and SLE 
susceptibility. However, the frequency of CT and TT genotypes was higher in SLE patients 
with LN than in those without LN. In addition, no correlation between OPN serum levels and 
rs1126616 polymorphism has been found.
In conclusion, a number of studies demonstrated that some OPN polymorphic variants are 
associated with SLE susceptibility and/or clinical manifestations of the disease in humans. 
However, some studies gave different or inconclusive results. Reasons for such divergences 
may be low statistical power or clinical variety. Only few studies evaluated the correlation coef-
ficient between OPN polymorphisms and SLE. Moreover, limited clinical data were provided.
3.2. Multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system (CNS) 
with the basic pathological hallmark of inflammatory demyelination in the white matter and 
cortex, implying a disturbance of the symbiotic relationship of the axon and myelin sheath 
[45]. Infiltrating CD4+ Th1 cells, which produce IFN-γ, and CD4+ Th17, which produce IL-17, 
has been shown to be involved in pathogenesis of MS. In addition, activated monocytes and 
B cells are present in the CNS, which results in degradation of the myelin sheath surrounding 
nerves [45, 46]. For MS development, both genetic predisposition and environmental factors 
are responsible [47]. OPN, a pleiotropic cytokine, plays an important role in immune-mediated 
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disorders. OPN may influence development of MS through enhancing the pro-inflammatory 
Th1 and Th17 cell responses and inhibiting the anti-inflammatory Th2 cell responses [11, 29].
In the literature, there are reports suggesting that OPN participates in the pathogenesis of 
MS. OPN was identified as one of the disease-specific markers in plaques from brains of 
patients with MS [48]. In addition, it has been demonstrated that this protein is expressed 
higher in blood and CNS in MS patients than in healthy controls [49]. Moreover, OPN level 
correlated positively with disease activity and relapse rate [50–53]. However, there are stud-
ies which showed that higher OPN serum level in MS patients is not associated with disease 
severity [54, 55].
A large body of data indicates that OPN gene variants have an impact on MS pathogenesis 
and progression.
In a study of Niino et al. [56], three SNPs in the OPN gene (8090 in a coding region of exon 6, 
9250 in a coding region of exon 7, and 9583 in the 3′-UTR region of exon 7) were analyzed in 
Japanese MS patients and healthy controls. It has been demonstrated that the CC genotype at 
the 8090th position was more prevalent in MS than in the control group. For the 9583rd posi-
tion polymorphism, patients with GG genotype showed a later disease onset than GA and 
AA genotypes. However, there were no significant correlations between OPN variants and 
disease progression. These results suggest that the 8090th polymorphism might be associated 
with susceptibility to MS, whereas the 9583rd polymorphism with age of onset of MS.
In another study, Caillier and colleagues [57] investigated whether four SNPs (327T/C, 
795C/T, 1128A/G, and 1284A/C) in the OPN gene were correlated with susceptibility to MS 
or clinical manifestations in a group of MS patients. As a result of the strong disequilibrium 
observed between SNPs within the OPN locus, only two SNPs were selected to study poten-
tial genotype-phenotype correlations: 1284A/C and 327T/C. No evidence of genetic associa-
tion between the OPN polymorphisms and MS susceptibility has been observed. However, 
a modest trend for association with disease course was detected in patients carrying at least 
one wild-type 1284A allele. Patients with this allele/genotype were less likely to have a mild 
disease course and were at increased risk for a secondary progressive clinical type.
Similar to study of Caillier et al., no evidence of association between OPN variants and MS 
susceptibility and severity was observed in a study of Hensiek et al. [58].
Chiocchetti et al. [59, 60] identified four SNPs in the OPN gene: +282T/C(rs4754), +750C/T 
(rs11226616), +1083A/G (rs1126772), and +1239A/C(rs9138) in 3′ UTR, which form three 
haplotypes: A (282T-750C-1083A-1239A), B (282C-750T-1083A-1239C), and C (282C-750T-
1083G-1239C). The group demonstrated that haplotype A homozygotes showed lower risk 
of developing MS and lower OPN serum levels than haplotype B or C carriers. In the next 
study, analysis was extended to a gene polymorphism at the 5′ end on the −156G/GG SNP and 
replicated previous findings at the 3′ end on the +1239A/C SNP. It has been demonstrated that 
+1239A/C SNP was associated with MS development. +1239A and −156/GG homozygosity 
was associated with slower disease progression. Moreover, patients homozygous for +1239A 
showed lower relapse rate than those carrying +1239C [61].
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Most of the results indicate that OPN and its gene SNPs might be a good marker for the 
susceptibility to and severity of MS. Despite this, further studies are needed to improve our 
understanding of the OPN gene role in disease pathogenesis.
3.3. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects joints, connective tis-
sues, muscle, tendons, and fibrous tissue [62]. In RA, immune cells (monocytes, macrophages, 
B cells, CD4+ and CD8+ T cells, neutrophils) infiltrate the synovial fluid. Activation of T cells 
leads to the production of pro-inflammatory cytokines. Humoral adaptive immunity is also 
integral to RA. B cells are activated through interactions with T cells and through soluble 
cytokines that enhance their proliferation and differentiation. Mature B cells (plasma cells) 
are a source of autoantibodies (known as rheumatoid factors and anti-citrullinated peptide 
antibodies, ACPA). Synovial macrophages produce pro-inflammatory cytokines, including 
tumor necrosis factor (TNF), IL-1, IL-6, IL-8, and granulocyte-macrophage colony-stimulating 
factor (GMCSF). Neutrophils in the synovial fluid are in an activated state, releasing oxygen-
derived free radicals that promote joints damage [63]. Gene-environment interactions appear 
as the most plausible underlying cause of RA.
A wide spectrum of immune mediators is currently under investigation in the context of RA 
pathogenesis and progression. One of them is OPN. This protein has been found to be elevated 
in plasma and synovial fluid of RA patients as well as in peripheral blood mononuclear cells 
(PBMCs) and synovial fluid mononuclear cells [64–66]. High OPN level has been correlated 
with serum C-reactive protein (CRP) level and inflammation markers [67]. It has been demon-
strated that OPN concentration is higher during disease progression. Moreover, OPN correlates 
with bone resorption markers [68]. To support the role of OPN in RA, several studies have been 
conducted to investigate the role of OPN gene variants in disease pathogenesis and progression.
In 2005, Urcelay et al. [69] studied the association of four OPN SNPs (327T/C in the coding 
region of exon 6, 795C/T in the coding region of exon 7, 1128A/G, and 1284A/C in the 3′-UTR) 
and predisposition to RA in a Spanish population. Analysis of the haplotypes defined by 
these SNPs did not identify association with RA.
In another study, Xu and colleagues [66] investigated whether genetic polymorphisms of the 
OPN gene were associated with susceptibility to RA in Chinese Han nationality. Analysis 
revealed a total of 14 SNPs. Finally, six SNPs were selected for analysis (two newly identi-
fied SNPs in the promoter region: −631G/T and −458T/C and four in exons: rs4754, rs1126616, 
rs1126772, rs9138). Similarly to a study of Urcelay et al., prevalence of OPN genotype and 
allele frequencies did not differ significantly between RA patients and healthy controls.
For the first time, the association between OPN gene polymorphism and RA susceptibility 
was demonstrated in a study of Ceccarelli et al. [70] in an Italian cohort. A statistically sig-
nificant association between RA and OPN −156G/GG (rs7687316) was found. There was no 
association of +1239A/C (rs9138) polymorphism and RA.
In 2013, Gazal et al. [71] evaluated the contribution of the OPN rs11439060 (−156-/G) and 
rs9138 (1239A/C) SNPs in a large cohort of RA patients and controls. The group reported a 
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significant contribution of the combination of the rs11439060 and rs9138 frequent alleles to 
risk of RA, especially in ACPA-negative patients. In the next study of this group, it has been 
demonstrated that rs9138 variants contribute to joint damage progression in ACPA-negative 
patients [72].
OPN is relatively a newly identified RA susceptibility gene. Data about the role of OPN vari-
ants in disease pathogenesis are very scanty and contradictory. Therefore, more studies are 
necessary for further elucidation of OPN polymorphism role in RA.
3.4. Systemic sclerosis
Systemic sclerosis (SSc) is an immune-mediated connective tissue disorder, characterized by 
an overproduction of collagen, immune dysfunction, and blood vessel damage [73]. Multiple 
organ damage is a consequence of this disease [74]. Immunological abnormalities of innate and 
adaptive immune system, including mononuclear cell infiltration of affected tissues, deregula-
tion of cytokines (transforming growth factor beta [TGFβ], TNFα, IL-6, IL-10, IL-17, IL-4, IL-13) 
and chemokines (CCL18, CCL19, CXCL13, CCL2, CCL3, CXCL4, CCR1, CCR2, CCR3) synthe-
sis, and autoantibodies production, have long been recognized in SSc [75].
Despite intense research, the pathogenesis of SSc is only partly understood, but it likely involves 
an interaction between environmental factors in a genetic predisposing background [76].
OPN, plays an important role during both acute and chronic inflammation. In the literature, there 
are reports suggesting that this protein participates in the pathogenesis of SSc. OPN has a che-
motactic and pro-fibrotic properties [77, 78]. Moreover, enhances the pro-inflammatory Th1 cell 
response, which is believed to be crucial in SSc pathogenesis. It has been demonstrated that mice 
with OPN overexpression have higher levels of anti-DNA autoantibodies, as well as increased 
gamma globulins [26]. This protein has been found to be elevated in plasma in SSc patients [79–81]. 
In addition, high OPN level was found to be correlated with serum CRP level [79].
The association between OPN gene polymorphisms and SSc susceptibility in humans has 
been investigated in a study of Barizzone et al. [82]. The group analyzed the association of 
two OPN SNPs: −156G/GG and +1239A/C and serum level of OPN in Italian SSc patients and 
controls. In SSc patients, there was a significantly increased frequency of the alleles −156G 
and +1239C, compared with controls. Moreover, OPN serum levels were significantly higher 
in SSc patients. However, no association between OPN levels and +1239 or −156 genotypes 
was observed.
These few data suggest that OPN genetic variations may have a role in SSc susceptibility, but 
further studies are needed to confirm these findings.
3.5. Inflammatory bowel diseases
Inflammatory bowel diseases (IBDs), especially Crohn’s disease (CD) and ulcerative colitis 
(UC), are idiopathic, multifactorial disorders, characterized by chronic intestinal inflamma-
tion [83]. CD is a transmural and segmental inflammatory disease. It may affect any part of the 
gastrointestinal tract, from the mouth to the anus, but is located usually in the terminal ileum. 
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It is characterized by the formation of ulcers, fistulas, stenosis, and intestinal granulomas, 
with periods of aggravation and remission. UC can affect only the mucosa of the colon and 
the rectum [84]. The etiology of IBDs is not fully elucidated. However, available evidence sug-
gests that an abnormal immune response against the microorganisms of the intestinal flora is 
responsible for the disease in genetically susceptible individuals [85]. CD is characterized as a 
Th1 directed disease, with elevated CD4+ T-cell synthesis of IFN-γ and high TNF-α and IL-12 
production by activated macrophages. UC is associated with incorrect Th2 response mediated 
by NKT cells, which secrete IL-13 [86].
In the literature, there are reports suggesting that OPN, as an immunomodulator, participates in 
the pathogenesis of IBDs in animal models and in humans. It has been demonstrated that serum 
OPN level is elevated in IBD patients and correlates with disease activity [87–91]. However, 
some studies in humans and in animal models of colitis gave opposite results, suggesting a dual 
or protective function of OPN in intestinal inflammation [86, 91–99].
The association between OPN gene polymorphisms and IBD susceptibility in humans has 
also been investigated. In a study of Glas et al. [100], 9 OPN SNPs (rs2728127, rs2853744, 
rs11730582, rs11739060, rs28357094, rs4754 = p.Asp80Asp, rs1126616 = p.Ala236Ala, rs1126772, 
and rs9138) were analyzed in a large group of Caucasian individuals ( 841 patients with 
CD,  473 patients with UC, and  1505 healthy unrelated controls). For rs4754, rs1126616, 
rs1126772, and rs9138, significantly different distributions between male and female CD 
patients were observed (rs4754 was protective in male patients). None of the other investi-
gated OPN SNPs was associated with CD or UC susceptibility. However, several haplotypes 
demonstrated significant associations with CD susceptibility. The strongest association was 
found for a haplotype rs2728127-rs2853744-rs11730582-rs11439060-rs28357094-rs112661-
rs1126772-rs9138. Moreover, no correlation was found between SNPs and IL-22 serum levels. 
The results argue against a major role for OPN gene polymorphism in the IBDs susceptibility. 
However, further analysis is required to clarify the role of OPN variants in the pathogenesis 
of the disease.
3.6. Type 1 diabetes
Type 1 diabetes (T1D) is a chronic, immune-mediated metabolic disorder of childhood and 
adolescence. T1D develops as a result of an autoimmune process, leading to β-cell destruction 
[101]. Activated NK cells, DCs, macrophages, and T-cells are attracted to the islets, which is 
followed by production of pro-inflammatory cytokines and free radicals, causing β-cell dys-
function and apoptosis [101, 102].
OPN plays an essential role in the regulation of immune cell response. It has been demon-
strated that OPN induces adipose tissue inflammation, upregulates pro-inflammatory cyto-
kines, and stimulates B lymphocytes to antibodies production. Consequently, OPN promotes 
the destruction of pancreatic β-cell and development of T1D [10, 103]. Therefore, several 
studies have been performed to assess the association of OPN and predisposition to T1D. 
This protein has been found to be elevated in pediatric and adult patients with T1D [104–
106]. Moreover, OPN has correlated with some clinical and biochemical parameters in T1D 
patients, including higher body mass index (BMI), systolic blood pressure (SBP), diastolic 
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blood pressure (DBP), lower high-density lipoprotein (HDL), and microalbuminuria [104, 
107]. In addition, OPN has been found to be an independent predictor of diabetic retinopathy 
and nephropathy [107].
The OPN encoding gene can be considered as a candidate for genetic susceptibility to T1D. 
Several studies have been conducted to investigate the role of OPN polymorphisms in disease 
pathogenesis. In 2009, Marciano et al. [108] genotyped T1D patients and controls for three 
OPN SNPs: −156G/GG, −66T/G (in promoter) and biallelic ins/del variant TG/TGTG at +245 
in the first intron. It has been demonstrated that the G allele at −66 SNP had higher frequency 
in controls than in patients. The association has been confirmed in females but not in males.
In another study, Chiocchietti and colleagues [109] evaluated the role of +1239A/C SNP in a 
3′-UTR of OPN gene in an Italian T1D patients and controls. The analysis revealed that C allele 
carriers displayed higher risk of T1D than A allele carriers. The group suggested that this SNP 
is associated with T1D development.
In 2013, a study of Karamizadeh et al. [105] showed that rs1126772 SNP is not associated with 
T1D children, although serum OPN levels were significantly higher in diabetic patients than 
in controls.
The results from these studies are inconclusive; thus, more research is necessary for further 
elucidation of OPN polymorphism role in T1D.
3.7. Asthma
Asthma is the most common chronic lung disease. It is characterized by airway inflammation 
and respiratory symptoms, such as wheeze, shortness of breath, chest tightness, and cough 
[110]. Multiple immune cells are involved in the inflammatory response in asthma. Th2 cells, 
which produce Il-4, IL-5, and IL-13, are responsible for eosinophils accumulation in the lungs 
of asthmatic patients. Th17 cells release IL-17 and recruit neutrophils, which attract eosino-
phils indirectly. Th1 and regulatory T (Treg) lymphocytes are also involved in the develop-
ment of asthma. An elevation of Th17 cells, the absence of Treg cells, and an imbalance in 
Treg/Th17 are associated with the disease [110–112].
Asthma is thought to be caused by a combination of genetic and environmental factors. 
A wide spectrum of immune mediators is currently under investigation in the context of 
this disorder. OPN plays an important role during inflammation and regulates function of 
immune cells. In the literature, there are reports suggesting that this protein participates in 
the pathogenesis of asthma. Several studies have demonstrated that OPN level is increased 
in asthmatic patients and is associated with disease phenotypes [113–116]. In addition, the 
chromosomal region of 4q24 (where OPN gene is mapped) has been associated with atopy in 
asthmatic patients [117]. These studies suggest that OPN gene may be a candidate gene for 
asthma susceptibility.
The case-control study of Tanino et al. [118] investigated the association of OPN variants with 
serum immunoglobulin E (IgE) levels, atopy, and asthma in a Japanese population. The group 
genotyped three promoters and two exon polymorphisms at OPN gene: −1687A/G; −381T/C; 
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−94 deletion/G; 5891C/T; and 7052T/C. Association analyses demonstrated that homozygotes 
for the 5891T allele and 7052C allele were significantly associated with increased levels of 
total IgE in non-asthmatic subjects. However, these variants were not associated with asthma 
and atopy.
Different results have been obtained in a study of Arjomandi and colleagues [119]. To deter-
mine whether SNPs in OPN gene are associated with risk of asthma, six SNPs (rs6812524, 
rs7435825, rs1126616, rs4660, rs1126772, and rs9138) have been genotyped in the Latino 
Americans population of 294 Mexican and 365 Puerto Rican parent-child asthma trios. 
Haplotype analysis identified rs1126616C-rs1126772A-rs9138A to be associated with an 
increased risk and severity of asthma in Puerto Rican subjects with elevated IgE. However, 
there was no association between the SNPs and asthma outcomes in Mexicans.
Only these two studies have been conducted to investigate the role of OPN gene variants 
in asthma pathogenesis and progression; therefore, further investigation in this field is 
indispensable.
3.8. Sarcoidosis
Sarcoidosis is a chronic inflammatory condition characterized by the formation of non-caseating 
epithelioid granulomata at various sites in the body (lungs, thorax, skin, eyes, liver, heart, and 
nervous and musculoskeletal system) [120]. The cause of the disease is still unknown, but sev-
eral immune aberrations are thought to play a role in its pathogenesis. Studies have revealed an 
increase of B-cell activity with elevated plasma levels of immunoglobulins and immune-com-
plexes in patients. In addition, inflammation in sarcoidosis is dependent on persistent stimula-
tion by CD4+ Th1 cells [120, 121]. Sarcoidosis is thought to be caused by a combination of genetic 
and environmental factors, but the exact etiology remains unclear. In the literature, there are 
reports suggesting that OPN participates in the pathogenesis of sarcoidosis. High levels of this 
protein have been found to be increased in serum and granulomas from patients with sarcoid-
osis [122–124]. Moreover, it has been demonstrated that OPN induced the chemotaxis of T cells 
and acted as an adhesion factor for activated T cells [123].
The OPN encoding gene can be considered as a candidate for susceptibility to sarcoidosis. 
Two studies have been conducted to investigate the role of OPN polymorphisms in disease 
pathogenesis. In 2004, Akahoshi et al. [125] investigated the 2514C/T SNP in Japanese patients 
with sarcoidosis and in healthy controls. The group did not find any significant association 
between genotypes/alleles and disease pathogenesis.
In another study, Maver and colleagues [126] genotyped three OPN SNPs: rs11730582, 
rs11728697, and rs4754 in Slovenian patients and healthy subjects. The analysis revealed a sig-
nificant difference in genotype frequencies at rs4754 SNP in patients and controls. However, 
these results failed to reach significance after correction for multiple testing. In addition, 
analysis demonstrated that frequency of rs11730582T-rs11728697T-rs4754T haplotype was 
decreased in the group of patients compared to controls. It has been suggested that TTT 
 haplotype of OPN gene is a protective factor in sarcoidosis.
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These scanty studies have yielded conflicting and inconclusive results. Thus, further analyses 
are required to understand the role of OPN and its gene polymorphism in sarcoidosis.
4. Conclusions and future perspectives
OPN is highly expressed by various cell types, including cells of the immune system. This 
pleiotropic protein regulates both, innate and adaptive immune response. A large number 
of publications suggest that OPN participates in the pathogenesis of multiple autoimmune 
conditions. Moreover, there are reports suggesting the role of OPN gene polymorphism in the 
pathogenesis and/or clinical manifestations of immune-mediated diseases. However, some 
investigations failed to demonstrate any associations of OPN SNPs with autoimmune condi-
tions. The main causes for these differences include ethnic, environmental and still unknown 
factors. Moreover, some studies do not meet the current rigorous standards for non-biased 
large-cohort trials. Future research should focus on selecting the best study groups to inves-
tigate the role of OPN variants in diseases pathogenesis and progression. Studies of OPN 
polymorphisms must take into account the gene-environment, gene-gene interactions, and 
ethnic factors.
The role of OPN polymorphic variants in autoimmune diseases needs to be better defined 
and explored as a diagnostic and therapeutic target to monitor and treat immune-mediated 
conditions. Advances in understanding specific SNPs in OPN may be helpful to create genetic 
profiles for predisposition to autoimmune diseases in order to adopt prevention strategies 
from childhood to adulthood.
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